LivaNova PLC
NASDAQ:LIVN

Watchlist Manager
LivaNova PLC Logo
LivaNova PLC
NASDAQ:LIVN
Watchlist
Price: 47.14 USD 0.83%
Market Cap: 2.6B USD
Have any thoughts about
LivaNova PLC?
Write Note

LivaNova PLC
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

LivaNova PLC
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
LivaNova PLC
NASDAQ:LIVN
Total Current Liabilities
$324.4m
CAGR 3-Years
-21%
CAGR 5-Years
-7%
CAGR 10-Years
29%
Smith & Nephew PLC
LSE:SN
Total Current Liabilities
$1.8B
CAGR 3-Years
-6%
CAGR 5-Years
4%
CAGR 10-Years
N/A
EKF Diagnostics Holdings PLC
LSE:EKF
Total Current Liabilities
ÂŁ5.4m
CAGR 3-Years
-33%
CAGR 5-Years
-19%
CAGR 10-Years
-9%
Angle PLC
LSE:AGL
Total Current Liabilities
ÂŁ4.6m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Total Current Liabilities
ÂŁ9.9m
CAGR 3-Years
-16%
CAGR 5-Years
16%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Total Current Liabilities
$3m
CAGR 3-Years
137%
CAGR 5-Years
65%
CAGR 10-Years
N/A
No Stocks Found

LivaNova PLC
Glance View

Market Cap
2.6B USD
Industry
Health Care

LivaNova PLC is a dynamic player in the realm of medical technology, with its roots tracing back to the merger of two well-established entities, Sorin Group and Cyberonics, in 2015. This union was more than just a blending of operations; it marked the convergence of expertise in cardiac surgery and neuromodulation. Headquartered in London, LivaNova set out with a mission to innovate within the treatment space for life-critical conditions, making a name for itself in the healthcare sector by focusing on two principal areas: cardiovascular solutions and neuromodulation therapy. These areas aren't just buzzwords; they represent the backbone of the company’s operations, serving critical patient needs with a near-requirement for continuous technological advancement. LivaNova's revenue streams are primarily derived from its cutting-edge products used in life-sustaining procedures and therapeutic interventions. In cardiovascular solutions, the company excels with its offerings in heart-lung machines, used in cardiac surgeries, and heart valves, instrumental in treating heart valve disease. Meanwhile, their neuromodulation division stands at the forefront of treating refractory epilepsy and depression with devices that deliver electrical impulses to the vagus nerve. By continuously pushing the envelope on medical tech, LivaNova not only ensures reliable outcomes for patients but also maintains a robust portfolio that draws revenues from hospitals and clinics worldwide. This balance of innovative prowess and strategic product deployment is what enables LivaNova to mitigate risks and sustain its financial health amidst the volatile landscape of the global healthcare market.

LIVN Intrinsic Value
80.78 USD
Undervaluation 42%
Intrinsic Value
Price

See Also

What is LivaNova PLC's Total Current Liabilities?
Total Current Liabilities
324.4m USD

Based on the financial report for Sep 30, 2024, LivaNova PLC's Total Current Liabilities amounts to 324.4m USD.

What is LivaNova PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
29%

Over the last year, the Total Current Liabilities growth was 10%. The average annual Total Current Liabilities growth rates for LivaNova PLC have been -21% over the past three years , -7% over the past five years , and 29% over the past ten years .

Back to Top